Oncolytics Highlights New Pelareorep Data in Cancer Immunotherapy

Oncolytics Biotech ( (ONCY) ) has issued an announcement.

On March 19, 2026, Oncolytics Biotech announced that new mechanistic and translational data on its lead immunotherapy pelareorep will be presented in two abstracts at the AACR 2026 Annual Meeting, covering metastatic pancreatic ductal adenocarcinoma and early-stage breast cancer. The presentations highlight pelareorep’s role as an immune‑priming backbone that activates innate and adaptive immune pathways, promotes tertiary lymphoid structure formation, and appears to enhance responses when combined with checkpoint inhibitors, chemotherapy, and other targeted therapies.

Data from Cohort 1 of the Phase 1/2 GOBLET trial in advanced pancreatic cancer show that pelareorep plus atezolizumab and gemcitabine/nab-paclitaxel can convert tumors to a more immune-active state, with a 14‑protein biomarker signature at week four correlating with longer median progression-free survival and previously reported response rates more than double historical chemotherapy benchmarks. Complementary AWARE-1 breast cancer findings demonstrate that pelareorep drives coordinated anti-tumor immune responses and tertiary lymphoid structure development in tumor tissue, supporting its potential to convert “cold” tumors to “hot” and reinforcing Oncolytics’ strategy to position pelareorep as a foundational combination partner across multiple RAS-driven and other hard-to-treat cancers.

Together, these results are likely to strengthen Oncolytics’ clinical narrative and partnering prospects by supplying biomarker-backed evidence that pelareorep can enhance the performance of existing immunotherapies and chemotherapies in high-unmet-need indications such as pancreatic and metastatic breast cancer. The data may also help refine patient selection through emerging immune activation signatures, potentially improving trial design and clarifying pelareorep’s role within the competitive immuno-oncology landscape.

The most recent analyst rating on (ONCY) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.

Spark’s Take on ONCY Stock

According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.

The score is held back primarily by weak financial performance (no revenue, sizable losses, heavy cash burn, and a sharply reduced equity base that raises financing risk). Technicals are a near-term positive with price above major moving averages and positive momentum indicators, while valuation remains difficult to support due to the negative P/E and lack of dividend.

To see Spark’s full report on ONCY stock, click here.

More about Oncolytics Biotech

Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent designed to convert immunologically “cold” tumors into “hot” ones. The company targets metastatic gastrointestinal and breast cancers, advancing pelareorep in combination with chemotherapy and checkpoint inhibitors, and holds FDA Fast Track designations for colorectal and pancreatic cancer.

Average Trading Volume: 1,343,466

Technical Sentiment Signal: Sell

Current Market Cap: $103.4M

Find detailed analytics on ONCY stock on TipRanks’ Stock Analysis page.